

# M2Bio Sciences Exhibits at The Cape Town Cannabis Expo 2023

CAPE TOWN, WESTERN CAPE, SOUTH AFRICA, March 24, 2023  
/EINPresswire.com/ -- Institute of Biomedical Research (OTC PINK: MRES) ("M2Bio Sciences" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update:

The biggest gathering of the Cannabis Industry in Africa returns for 2023 and kicks off the year in Cape Town, South Africa. Taking place annually in major business hubs across South Africa, The Cannabis Expo is the largest trade and consumer expo of its kind on the African continent and includes the Exhibition Hall, networking and entertainment spaces, The Cannabis Food Market as well as The Cannabis Convention that hosts moderated panel discussions and presentations from global industry leaders. Nicola Royce, Managing Director of M2Biome Cardiometabolic Health will be delivering a talk at 10:30 am on Saturday entitled: CBD & Diabetes Microvascular Complications.

This multifaceted event hosts over 200 exhibitors with more than 1000 cannabis products and provides the perfect platform for international and



local medical health professionals, agricultural providers, and lifestyle brands to engage with industry experts and the public around this versatile plant.

As pioneers in the industry, M2Bio Sciences will be showcasing two of its premium consumer CBD-infused brands – Medspresso™ and Liviana™ .

“We are excited to be back and once again be a part of this cutting edge event, as our debut at the Cannabis Expo in Sandton, Johannesburg last year was a roaring success and we hope to expand on this, this coming weekend.” - Jeff Robinson, CEO of M2Bio Sciences.

You can visit us at booth No. 17 at this year’s Cannabis Expo at Sun Exhibits, GrandWest in Cape Town from 24-26 March 2023.

About Institute of Biomedical Research Corp./ DBA M2Bio Sciences

Institute of Biomedical Research Corp, is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol "MRES".

Publicly traded company (OTC Pink:MRES)

Website: [www.m2bio.co](http://www.m2bio.co)

E-mail: [info@m2bio.co](mailto:info@m2bio.co)

Find Liviana™ on social media

Follow us on Facebook: [Liviana.Health](https://www.facebook.com/Liviana.Health)

Follow us on Instagram: [@liviana.health](https://www.instagram.com/liviana.health)

Follow us on LinkedIn: [Liviana™ Health](https://www.linkedin.com/company/liviana-health)

Find Medspresso™ on social media

Follow us on Facebook: [MedspressoFB](https://www.facebook.com/MedspressoFB)

Follow us on Instagram: [@medspresso.official](https://www.instagram.com/medspresso.official)

Follow us on LinkedIn: [Medspresso™ - More Than Just Coffee](https://www.linkedin.com/company/medspresso)

Forward-Looking Statements:

Safe Harbour Statement - In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the

intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward-looking statements.

Jeff Robinson  
M2Bio Sciences Food and Beverage (Pty) Ltd  
+27 72 333 2148

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[Instagram](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/624168991>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.